A novel mRNA cancer vaccine helps reduce the chances of melanoma patients’ tumors returning

Associated Press

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients’ tumors returning

LAURAN NEERGAARD
Updated
4 min read

Moderna Cancer Vaccine
In this image made from video, Tony Hout, left, talks with Dr. Hussein Tawbi at UT MD Anderson Cancer Center in Houston, Monday, Oct. 19, 2026. (AP Photo/Lekan Oyekanmi) (AP Photo/Lekan Oyekanmi)

WASHINGTON (AP) — A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.

The vaccine was custom-brewed for each patient to match their tumor. Adding it to a standard post-surgery treatment reduced by 42% the risk of melanoma returning two years after surgery, according to the most advanced study to date of this new strategy for fighting cancer.

“The field has been looking for a win and I think this one is a big one,” said Dr. Hussein Tawbi of MD Anderson Cancer Center in Houston, one of the researchers in the international study.

Advertisement